NCT02322320: Phase 3 - Continued, Long-Term Follow-Up and Lenalidomide Maint. (BMT CTN 07LT)
Updated: Mar 28, 2022
STaMINA Trial follow up
Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)
NCT02322320: Phase 3 - Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)
This study is designed to compare long-term outcomes among patients randomized on the BMT CTN 0702 protocol (NCT01109004), "A Trial of Single Autologous Transplant with or without Consolidation Therapy versus Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Multiple Myeloma". It is hypothesized that use of novel anti-myeloma agents will improve long-term progression-free survival (PFS) after high-dose melphalan followed by autologous hematopoietic cell transplantation (HCT) as compared to a second autologous transplantation.
Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Collaborators:
Blood and Marrow Transplant Clinical Trials Network
National Cancer Institute (NCI)
National Marrow Donor Program
ClinicalTrials.gov Identifier: NCT02322320
Official Title: Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)
* Bortezomib (Velcade)
* Lenalidomide (Revlimid)
* Dexamethasone (Decadron)
NCT01109004: Phase 3 - Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)
Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM).
2020 ASCO Annual Meeting
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial
J Clin Oncol; 2019
MASS-FIX versus standard methods to predict for PFS and OS among multiple myeloma patients participating on the STAMINA trial.
Conclusions: Mass-Fix is a powerful means to track monoclonal proteins. The full utility of Mass-Fix was not exploited given the absence of a diagnostic sample and the fact that only serum (and not urine) was tested. Despite these limitations, it performed well at pre-induction and at 1 year. Mass-Fix provides a convenient and non-invasive means of predicting for myeloma outcomes. Clinical trial information: NCT01109004
2021 ASCO Annual Meeting
- Multiple locations
- California: City of Hope Duarte
- California: University of California San Francisco
- Colorado: Sarah Cannon/Colorado Blood Cancer Institute Denver
- Florida: Moffitt Cancer Center Tampa
- Illinois: Rush University Medical Center Chicago
- Illinois: University of Chicago
- Massachusetts: Massachusetts General Hospital Boston
- Missouri: Washington University School of Medicine Saint Louis
- New Jersey: Hackensack University Medical Center
- New York: Memorial Sloan-Kettering Cancer Center New York
- New York: Tisch Cancer Institute Mount Sinai Hospital New York
- New York: Roswell Park Cancer Institute Buffalo
- New York: University of Rochester New York
- North Carolina: Wake Forest Baptist Health Winston-Salem
- Pennsylvania: University of Pennsylvania Philadelphia
- Tennessee: Sarah Cannon Research Institute Nashville
- Texas: The University of Texas MD Anderson Cancer Center Houston
- Texas: UT Southwestern Medical Center Dallas
- Texas: Baylor University Medical Center Dallas
- Washington: Fred Hutchinson Cancer Center Seattle